M CAP X CRP X DEX

 A

Here’s a summary with bullet points and key quotes from the recent findings on CRP-stratified steroid prescribing for severe community-acquired pneumonia (CAP):

---

🔍 Study Summary: CRP-Stratified Steroid Use in Severe CAP

Source:

• Smit JM et al., Lancet Respir Med, March 2025

• Commentary by Reyes LF and Martin-Loeches I, Lancet Respir Med, March 2025

---

📌 Key Points:

• CRP as a Decision Tool:
  C-reactive protein (CRP) levels at admission can stratify patients and help determine who benefits most from corticosteroids in severe CAP.

• Trial Design:

  • Double-blind, placebo-controlled, randomized trial

  • Patients hospitalized with severe CAP

  • Stratified into CRP ≥150 mg/L vs. CRP <150 mg/L

  • Dexamethasone used as corticosteroid

• Main Findings:

  • Steroids reduced treatment failure significantly in patients with CRP ≥150 mg/L

  • No clear benefit—and potential harm—in those with CRP <150 mg/L

  • Suggests that inflammation-driven approach is more precise and safer than blanket steroid use

• Potential Impact:
  CRP-guided therapy could personalize treatment, reduce overtreatment, and avoid side effects of steroids in low-CRP cases.

---

🧠 Notable Quotes:

• “CRP ≥150 mg/L identifies a subgroup most likely to benefit from adjunctive corticosteroid therapy.”

• “Precision medicine in pneumonia is not a futuristic concept—it’s actionable now through biomarkers like CRP.”

• “This approach moves us closer to targeted anti-inflammatory treatment rather than generalized immunosuppression.”

---

Let me know if you'd like this in a clinical handout format or if you're looking for similar stratified approaches in other conditions.